TABLE 1.
Clinicodemographic characteristics (n = 312)
| Characteristic | No. (%) |
|---|---|
| Age, years | |
| Median (range) | 65 (22–88) |
| >60 | 212 (67.9) |
| >70 | 78 (25.0) |
| Sex, male | 182 (58.3) |
| ECOG performance status >1 | 56 (17.9) |
| B symptom present | 150 (48.1) |
| Ann Arbor stage, III–IV | 289 (92.6) |
| LDH > ULN | 181/303 (59.7) |
| Albumin level < 35 g/L | 104/305 (34.1) |
| IgG level > 17 g/L | 33/75 (44.0) |
| CRP > ULN | 141/187 (75.4) |
| β2‐MG > ULN | 146/228 (64.0) |
| Anemia a | 140/304 (46.1) |
| Platelet count <100 × 109/L | 37/304 (12.2) |
| Positive HBsAg | 30/299 (9.5) |
| EBV‐DNA ≥500 copies/mL | 66/185 b (35.7) |
| No. of extranodal sites ≥2 | 80/312 (25.6) |
| Extranodal sites | |
| Spleen | 100 (32.1) |
| Lung | 20 (6.4) |
| Skin | 19 (6.1) |
| Liver | 10 (3.2) |
| Bone marrow | 58 (18.6) |
| IPI score | |
| 0–1 (Low risk) | 48/299 (16.1) |
| 2 (Low‐intermediate risk) | 109/299 (36.5) |
| 3 (High‐intermediate risk) | 82/299 (27.4) |
| 4–5 (High risk) | 50/299 (16.7) |
| PIT score | |
| 0 (Group 1) | 37/299 (12.4) |
| 1 (Group 2) | 115/299 (38.5) |
| 2 (Group 3) | 99/299 (33.1) |
| 3–4 (Group 4) | 48/299 (16.1) |
Abbreviations: AITL, angioimmunoblastic T‐cell lymphoma; CRP, C‐reactive protein; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; HBsAg, hepatitis B virus surface antigen; IgG, gamma globulin; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PIT, Prognostic Index for T‐cell lymphoma; ULN, upper limit of normal; β2‐MG, β2‐microglobulin.
a
Hemoglobin level < 120 g/L in men and 110 g/L in women.
b
Of the 185 cases, 61 were measured in whole blood., and the rest were measured in cell‐free plasma.